Abstract 551P
Background
The use of immune checkpoint inhibitors (ICI) has transformed the management of non-small cell lung cancer (NSCLC). With improved cancer outcomes have come increased auto-immune toxicities, which could affect any organ system. We investigated the incidence and outcomes of immune-related adverse events (irAE) in a large cohort of NSCLC patients.
Methods
Medical records from a metropolitan cancer centre in the AUstralian Registry and biObank of thoRAcic cancers (AURORA) registry were reviewed. Kaplan Meier analysis was used for survival estimates. Risk factors were tested using Fishers Exact test and logistic regression. False discovery rate of 5% was used to correct for multiple testing.
Results
Between 2013-2021, 449 patients received ICI. The median age was 65 years, 61% were male. Most (91%) had an ECOG of 0-1, 68% had metastatic disease at diagnosis, and 70% had adenocarcinoma. ICI was given as first line treatment in 47% of patients, and 22% had curative intent therapy. irAE were identified in 106 patients (24%). Most frequent was pneumonitis in 34 patients (incidence 7.6%); followed by colitis in 21 (4.5%), acute kidney injury in 19 (4.2%), thyroid disorders in 14 (3.1%), hepatitis in 12 (2.7%), skin toxicity in eight (1.8%), myositis in four (0.9%) and cardiac disorders and hypoadrenalism in three (0.7%) each. Toxicities noted twice included: arthropathy, hypoadrenalism, encephalitis, blood dyscrasias, diabetes, and ocular toxicities. Diabetes, gastritis and enteritis were identified in one patient each. Nineteen (4.2%) patients had two toxicities, one patient recorded three toxicities and one had four. No relationship was found between irAE and ICI combination therapy, smoking, age, performance status, or sex. The rate of pneumonitis was higher in those with airways disease than in those without (OR 14.81, 95% CI 6.64-33.59, P<0.01). Median overall survival in those with irAE was 18.7 months, versus 9.2 months in those without (HR 0.54, 95%CI 0.42-0.70, P=<0.01).
Conclusions
In a real word cohort, immune-related toxicities were similar to those reported in the literature. The development of irAE was associated with improved survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B. Solomon: Financial Interests, Institutional, Advisory Board: AstraZeneca, Novartis, Merck, Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Roche/Genentech; Financial Interests, Personal, Advisory Board: Amgen, Roche-Genentech, Eli Lilly, Takeda, Janssen; Financial Interests, Personal, Full or part-time Employment, Employed as a consultant Medical Oncologist at Peter MacCallum Cancer Centre: Peter MacCallum Cancer Centre; Financial Interests, Personal, Member of Board of Directors: Cancer Council of Victoria, Thoracic Oncology Group of Australasia; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Steering Committee Member, Principal Investigator and Steering committee Chair: Roche/Genentech, Pfizer; Financial Interests, Institutional, Steering Committee Member: Novartis. M. Alexander: Financial Interests, Personal, Advisory Board: BMS/Pfizer. T. John: Financial Interests, Personal, Invited Speaker, Speaker tour Vietnam: AstraZeneca; Financial Interests, Personal, Invited Speaker, CTIO: Merck Sharp Dohme; Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Bayer, Specialised Therapeutics; Financial Interests, Institutional, Advisory Board: Roche, Novartis, Pfizer, Amgen, Takeda, PharmaMar; Financial Interests, Personal, Other, Speaker/Chair: ACE Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract